The global Ensartinib market is experiencing a transformative phase, driven by advancements in oncology research and the increasing prevalence of non-small cell lung cancer (NSCLC). According to a recent report by Dataintelo, the market is projected to grow at a robust CAGR of 8.5% from 2023 to 2032, reaching a valuation of USD 1.2 billion by the end of the forecast period. This growth is...